A multicentre outcome research in daily clinical practice concerning the prevention of acute and delayed nausea and vomiting after chemotherapy: an outcome research

Not Applicable

Completed

• Conditions: Quality of life and chemotherapy induced nausea and vomiting; Signs and Symptoms; Digestive symptoms

• Registration Number: ISRCTN55375237
• Lead Sponsor: Medical Centre Alkmaar (Medisch Centrum Alkmaar) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-07-16
• Study Completion: 2007-09-01
• Last Update Posted: 8 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 600

Inclusion Criteria

Chemotherapy naive patients receiving chemotherapy.

Exclusion Criteria

1. Life expectancy less than three months
2. Lack of basic proficiency in Dutch
3. Age below 18
4. Pregnancy
5. Psychological illness

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. To make an inventory on the anti-emetic policy in several peripheral hospitals<br> 2. To make an inventory on the effectiveness of these anti-emetic policies<br>

Secondary Outcome Measures

Name	Time	Method
<br> 1. What is the difference in anti-emetic policies used in several peripheral hospitals?<br> 2. Do these anti-emetic policies correspond with evidence based guidelines?<br> 3. Is aprepitant used in high emetogenic chemotherapy treatment or moderate emetogenic chemotherapy treatment?<br> 4. What is the incidence of acute and delayed nausea and vomiting in chemotherapy treatment and does this correspond with literature?<br> 5. Can differences in effectiveness be explained by differences in patient characteristics, chemotherapy and/or anti-emetic policy?<br>